OXFORD, United Kingdom and MARLBOROUGH, Mass., March 23, 2017 (GLOBE NEWSWIRE) -- Oxford Immunotec Global PLC (Nasdaq:OXFD), a global, high-growth diagnostics company focused on developing and commercializing proprietary tests for the management of underserved immune-regulated conditions, today announced the release of national T-SPOT®.TB test positivity rates within the United States and United Kingdom, as well as a grant to support TB screening for high risk patients.
Today, only active TB infections are reported to the Centers for Disease Control and Prevention in the U.S. and National Health Services in the U.K. Patients with latent TB infections far outnumber those with active TB disease, but consolidating test results from multiple sources makes this challenging to track.
Oxford Immunotec has compiled a unique data set of T-SPOT.TB test results for both the United States and the United Kingdom through its Oxford Diagnostic Laboratories®’ testing services. This data provides a representative overview of the positivity rate of T-SPOT.TB tests in 2016 by state and region, and is shown in three heat maps:
- U.S. T-SPOT.TB test positive rates by state
- U.K. T-SPOT.TB test positive rates by region
- U.S. T-SPOT.TB test positive rates by state for customers who serve patients at higher risk of developing active TB. (High risk populations in this data set include contact investigations, refugees, HIV patients and patients on immunosuppressive therapy.)
Further, the Company announced that they have provided a grant for tuberculosis screening to the Florida Department of Health – Hillsborough County. This grant will allow the Florida Department of Health to screen up to 250 additional high-risk patients on World TB Day.
About Oxford Immunotec
Oxford Immunotec Global PLC is a global, high-growth diagnostics company focused on developing and commercializing proprietary tests for the management of underserved immune-regulated conditions. The Company’s first product is the T-SPOT.TB test, which is used to test for tuberculosis infection. The T-SPOT.TB test has been approved for sale in over 50 countries, including the United States, where it has received pre-market approval from the Food and Drug Administration, Europe, where it has obtained a CE mark, as well as Japan and China. The Company’s second product line is a range of assays for tick-borne diseases, such as Lyme disease, obtained through the acquisitions of Imugen and Immunetics. Also obtained through the acquisitions is the Company’s third product line focused on screening for Babesia in donated blood, for which the Company is currently seeking FDA clearance. The T-SPOT.CMV test and the T-SPOT.PRT test are pipeline products as part of the Company’s fourth intended product line focused on the transplantation market. In addition to these four product lines, the Company has additional active development programs in other immune-regulated conditions. The Company is headquartered near Oxford, U.K. and in Marlborough, Mass. Additional information can be found at www.oxfordimmunotec.com.
T-SPOT and the Oxford Immunotec logo are trademarks of Oxford Immunotec Ltd. Immunetics is a trademark of Immunetics, Inc.
For Media Inquiries:
Tel: +44 1235 442796
For Investor Inquiries:
Chief Financial Officer
Tel: +1 (508) 573-9953
Tel: +1 (443) 213-0501